SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), today announced it has finalized a Material Transfer Agreement (MTA) with Celgene Cellular Therapeutics (CCT). As part of the agreement, ImmuneRegen will ship its potential therapeutic Homspera® to CCT for testing.
